Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc.

AMRX

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Regular session

$17.692

−$0.088 · -0.49%

Aug 25, 1:18 PM ET

AMRX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

61

Undervalued

Momentum

67

Gaining

Sentiment

64

Bullish

Risk resilience

66

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Chirag K. Patel
Listed since
May 7, 2018
Employees
8,700

Market position

Day range

Current $17.692

52-week range

Current $17.692

Open
$17.78
Previous close
$17.78
Volume
289.55K
0.15× average
Average volume
1.89M
Average daily volume
Market cap
5.65B USD
Beta
1.26
Market reference 1
50-day average
$17.5358
+0.89% above average
200-day average
$14.0959
+25.51% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
6.37B USD
P/E (TTM)
35.57×
P/B (TTM)
171.03×
P/S (TTM)
1.81×
EV / EBITDA
10.56×
Earnings yield
1.82%
Free cash flow yield
6.84%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
39.32%
Operating margin
12.93%
Net margin
5.05%
Return on equity
-101.78%
Return on assets
1.96%
Return on invested capital
13.80%

Financial health

Debt / equity
84.54×
Current ratio
2.17×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends42%25%7%-10%Gross margin, FY2021: 36.73%Gross margin, FY2022: 35.78%Gross margin, FY2023: 36.09%Gross margin, FY2024: 36.52%Gross margin, FY2025: 37.63%Operating margin, FY2021: 7.29%Operating margin, FY2022: -4.29%Operating margin, FY2023: 8.54%Operating margin, FY2024: 8.92%Operating margin, FY2025: 14.02%Net margin, FY2021: 0.51%Net margin, FY2022: -5.88%Net margin, FY2023: -3.51%Net margin, FY2024: -4.18%Net margin, FY2025: 2.39%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 36.73%. Gross margin FY2022 35.78%. Gross margin FY2023 36.09%. Gross margin FY2024 36.52%. Gross margin FY2025 37.63%. Operating margin FY2021 7.29%. Operating margin FY2022 -4.29%. Operating margin FY2023 8.54%. Operating margin FY2024 8.92%. Operating margin FY2025 14.02%. Net margin FY2021 0.51%. Net margin FY2022 -5.88%. Net margin FY2023 -3.51%. Net margin FY2024 -4.18%. Net margin FY2025 2.39%.

Income trends

Revenue

3.02B USD+8.05%

Operating income

423.09M USD+69.69%

Net income

72.06M USD+188.94M USD
Income trends across reported periods3.33B USD2.07B USD814.64M USD−444.86M USDRevenue, FY2021: 2.09B USDRevenue, FY2022: 2.21B USDRevenue, FY2023: 2.39B USDRevenue, FY2024: 2.79B USDRevenue, FY2025: 3.02B USDOperating income, FY2021: 152.72M USDOperating income, FY2022: −94.93M USDOperating income, FY2023: 204.37M USDOperating income, FY2024: 249.33M USDOperating income, FY2025: 423.09M USDNet income, FY2021: 10.62M USDNet income, FY2022: −129.99M USDNet income, FY2023: −83.99M USDNet income, FY2024: −116.89M USDNet income, FY2025: 72.06M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.09B USD. Revenue FY2022 2.21B USD. Revenue FY2023 2.39B USD. Revenue FY2024 2.79B USD. Revenue FY2025 3.02B USD. Operating income FY2021 152.72M USD. Operating income FY2022 −94.93M USD. Operating income FY2023 204.37M USD. Operating income FY2024 249.33M USD. Operating income FY2025 423.09M USD. Net income FY2021 10.62M USD. Net income FY2022 −129.99M USD. Net income FY2023 −83.99M USD. Net income FY2024 −116.89M USD. Net income FY2025 72.06M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.02B USD2.79B USD2.39B USD2.21B USD2.09B USD
Cost of goods sold1.88B USD1.77B USD1.53B USD1.42B USD1.32B USD
Gross profit1.14B USD1.02B USD863.87M USD791.46M USD768.97M USD
Research and development186.18M USD190.71M USD194.75M USD208.66M USD209.56M USD
Selling, general, and administrative526.83M USD476.44M USD429.68M USD399.7M USD365.5M USD
Operating expenses713M USD771.11M USD659.5M USD886.39M USD616.26M USD
Interest expense241.09M USD258.6M USD210.63M USD158.38M USD136.33M USD
Depreciation and amortization223.57M USD236.19M USD229.4M USD240.18M USD233.41M USD
Operating income423.09M USD249.33M USD204.37M USD−94.93M USD152.72M USD
Net income72.06M USD−116.89M USD−83.99M USD−129.99M USD10.62M USD

Company facts updated Aug 25, 2026.

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
+35.72%
11 comparable reports
Latest EPS result
0.3
Estimate 0.22 · Beat by 34.83%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.340.260.180.1Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 28, 2025: actual 0.12, estimate 0.15, surprise -20.00%, Miss. Q2 2025, reported May 2, 2025: actual 0.21, estimate 0.15, surprise +40.00%, Beat. Q3 2025, reported Aug 5, 2025: actual 0.25, estimate 0.18, surprise +38.89%, Beat. Q4 2025, reported Oct 30, 2025: actual 0.17, estimate 0.13, surprise +30.77%, Beat. Q1 2026, reported Feb 27, 2026: actual 0.21, estimate 0.18, surprise +16.67%, Beat. Q2 2026, reported May 7, 2026: actual 0.27, estimate 0.17, surprise +58.82%, Beat. Q3 2026, reported Jul 30, 2026: actual 0.3, estimate 0.223, surprise +34.83%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 0.26, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates846.89M785.54M724.2M662.85MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 28, 2025: actual 730.52M USD, estimate 723.09M USD, surprise +1.03%, Beat. Q2 2025, reported May 2, 2025: actual 695.42M USD, estimate 744.23M USD, surprise -6.56%, Miss. Q3 2025, reported Aug 5, 2025: actual 724.51M USD, estimate 768.6M USD, surprise -5.74%, Miss. Q4 2025, reported Oct 30, 2025: actual 784.51M USD, estimate 806.07M USD, surprise -2.67%, Miss. Q1 2026, reported Feb 27, 2026: actual 814.32M USD, estimate 807.35M USD, surprise +0.86%, Beat. Q2 2026, reported May 7, 2026: actual 722.52M USD, estimate 719.66M USD, surprise +0.40%, Beat. Q3 2026, reported Jul 30, 2026: actual 796.2M USD, estimate 768.21M USD, surprise +3.64%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 808.55M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

17 ratings
Strong buy00%
Buy1165%
Hold635%
Sell00%
Strong sell00%

AMRX peers

ETFs holding AMRX

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research AMRX

research.disclaimer